OncoSec Medical (ONCS) Stock Price, News & Analysis

Company Overview

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.20 to $0.94
• 52-Week Range: N/A
• Volume: 52.49 million shs
• Average Volume: 2.22 million shs
• Market Capitalization: $1.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONCS Stock Analysis - Frequently Asked Questions

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) announced its quarterly earnings data on Tuesday, December, 14th. The biotechnology company reported ($5.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($8.14) by $2.64.

When did OncoSec Medical's stock split?

OncoSec Medical shares reverse split before market open on Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), XOMA (XOMA), Amarin (AMRN) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 12/14/2021
• Today: 2/22/2025
• Fiscal Year End: 7/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ONCS
• CUSIP: N/A
• CIK: 1444307
• Web: www.oncosec.com
• Phone: (855) 662-6732
• Fax: 858-430-3832
• Employees: 40
• Year Founded: 2011

Profitability

• EPS (Most Recent Fiscal Year): ($15.2865)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-34,180,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -868.29%
• Return on Assets: -160.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.89
• Quick Ratio: 0.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.42 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,550,000
• Free Float: 4,494,000
• Market Cap: $1.26 million
• Optionable: Not Optionable
• Beta: 1.99